Revised SPC: Xaluprine (mercaptopurine monohydrate) 20 mg/ml oral suspension
Portal hypertension, nodular regenerative hyperplasia and sinusoidal obstruction syndrome added as adverse effects of treatment with unknown frequency (reported in patients with inflammatory bowel disease – an unlicensed indication).
Source:
electronic Medicines compendium